A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | AA | AB | AC | AD | AE | AF | AG | AH | AI | AJ | AK | AL | AM | AN | AO | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Deal Date | R&D | Client | Deal Types | Stages | Deal Subject | Deal Link | Size ($M) | Equity ($M) | Maximum Share (%) | Contracts | PRs | Deal Source | Exclusivity | Diseases | Indications | Technologies | Sub Technologies | Territory | Compound Name | MOA Category | Mechanism of Action | Molecular Target | Drug Mode of Action | Upfront Cash ($M) | Upfront Equity ($M) | Contingent Equity ($M) | R&D Support ($M) | FTE Rate ($M) | Loan ($M) | Dev / Reg Milestones ($M) | Other Milestones ($M) | Total Precommercial Payments ($M) | Sales Milestones ($M) | Deal Size ($M) | Maximum Royalty (%) | Marketing Fee (%) | Transfer Price (%) | Manufacture Cost + (%) | Profit Split (%) | Financial Term Explanations |
2 | 10/2020 | AgeX Therapeutics | ImStem Biotechnology | Sublicense | Preclinical | IMS001 cell therapy candidate for COVID-19 and acute respiratory distress syndrome | Link | Yes | PR | Non-exclusive | Infectious-Viral, Respiratory | Coronavirus, Other Respiratory | Cell Therapy - Stem Cells/Factors | ||||||||||||||||||||||||||||
3 | 10/2020 | Molecular Partners | Novartis | Equity, License, Option | Preclinical | MP0420 and MP0423 DARPin therapeutics for prevent and treat COVID-19 | Link | 231.00 | Yes | PR | Infectious-Viral | Coronavirus | 22.00 | 44.00 | 231.00 | 22.00 | CHF 20 million (US$22M) | CHF 40 million (US$44M) worth of ordinary shares, at a price of CHF 23 (US$25)/share, representing 6% equity stake | CHF 150 million (US$165M), upon Novartis exercising the option to both therapeutic candidates | ||||||||||||||||||||||||
4 | 10/2020 | Global Coalition for Adaptive Research | Eisai, Amgen | Research | Evaluation of apremilast and eritoran in REMAP-COVID clinical study | Link | Yes | PR | Infectious-Viral | Coronavirus | |||||||||||||||||||||||||||||||
5 | 10/2020 | Histogen | Amerimmune | Co-Development, License, Option | Preclinical | Emricasan pan-caspase inhibitor to treat COVID-19 | Link | Yes | PR | Infectious-Viral | Coronavirus | Synthetics | Small Molecule | ||||||||||||||||||||||||||||
6 | 10/2020 | George Mason University | Targeted Pharmaceutical | Research | Preclinical | Preclinical evaluation of ARDS-003 to prevent & treat COVID-19 | Link | Yes | PR | Infectious-Viral | Coronavirus | ||||||||||||||||||||||||||||||
7 | 10/2020 | Infectious Disease Research Institute | Amyris | License | RNA vaccine platform to develop COVID-19 vaccine, plus three additional indications | Link | Yes | PR | Infectious-Viral, Unlimited | Coronavirus | Vaccines | ||||||||||||||||||||||||||||||
8 | 10/2020 | ADial Pharmaceuticals | Todos Medical | Distribution, License | Diagnostic | COVID-19 point of care rapid test devices | Link | Yes | PR | Non-exclusive | Infectious-Viral | Coronavirus | Diagnostics | ||||||||||||||||||||||||||||
9 | 10/2020 | ADial Pharmaceuticals | Avalon GloboCare | Distribution, License | Diagnostic | COVID-19 point of care rapid test devices | Link | Yes | PR | Non-exclusive | Infectious-Viral | Coronavirus | Diagnostics | Worldwide | |||||||||||||||||||||||||||
10 | 10/2020 | Atea Pharmaceuticals | Roche | Co-Development, License | Phase II | AT-527 oral direct-acting antiviral to treat COVID-19 ex-US | Link | 1,000.00 | Yes | Yes | SEC Redacted | Exclusive | Infectious-Viral | Coronavirus | Synthetics | Small Molecule | Africa, Asia, Europe, Middle East, NAFTA, South America | AT-527 | Antiviral | 2019-nCoV (SARS-CoV-2) (COVID-19) | 350.00 | 330.00 | 680.00 | 320.00 | 1,000.00 | low double-digit to mid-twenties royalties, per Atea's IPO prospectus | |||||||||||||||
11 | 10/2020 | Samsung Biologics | DiNonA | CSO | Services to support development of DNP-019 antibody therapy. for COVID-19 | Link | Yes | PR | Infectious-Viral | Coronavirus | Monoclonals | DNP-019 | Antibody | 2019-nCoV (SARS-CoV-2) (COVID-19) | |||||||||||||||||||||||||||
12 | 10/2020 | McMaster University | SQI Diagnostics | Research | Diagnostic | Technology to measure severity of COVID-19 | Link | Yes | PR | Infectious-Viral | Coronavirus | Diagnostics | |||||||||||||||||||||||||||||
13 | 10/2020 | Nature Technology Corporation | Aegis Life | License | Nanoplasmid plasmid DNA technology and manufacturing platform for SARS-CoV-2 vaccine | Link | Yes | PR | Infectious-Viral | Coronavirus | Vaccines | ||||||||||||||||||||||||||||||
14 | 10/2020 | Entos Pharmaceuticals | Aegis Life | License | Spin out of Aegis Life to develop SARS-CoV-2 vaccine using Entos Fusogenix technology | Link | Yes | PR | Infectious-Viral | Coronavirus | Vaccines | ||||||||||||||||||||||||||||||
15 | 10/2020 | TScan Therapeutics | Poseida Therapeutics | License, Research | Discovery | Evaluation of allogeneic T Cell receptor therapies to treat COVID-19 | Link | Yes | PR | Infectious-Viral | Coronavirus | Cell Therapy - Stem Cells/Factors | |||||||||||||||||||||||||||||
16 | 10/2020 | Lactiga, Mount Sinai Health System | NIH | Research | Preclinical | NIH funding to advance preclinical research of LCTG-001 as potential treatment for COVID-19 | Link | Yes | PR | Infectious-Viral | Coronavirus | LCTG-001 | Antiviral | 2019-nCoV (SARS-CoV-2) (COVID-19) | |||||||||||||||||||||||||||
17 | 10/2020 | Yokohama City University, National Center for Global Health and Medicine, KAN Research Institute, Nagasaki University | Eisai | Research | Preclinical | Development of therapeutics for COVID-19, including preclinical evaluation of eritoran and E6011 | Link | Yes | PR | Infectious-Viral | Coronavirus | Monoclonals, Synthetics | Small Molecule | ||||||||||||||||||||||||||||
18 | 10/2020 | University of Houston | AuraVax Therapeutics | License, Option | IP covering intranasal vaccine technology for development of COVID-19 vaccine | Link | Yes | PR | Infectious-Viral, Respiratory | Coronavirus | Drug Delivery, Vaccines | Nasal | |||||||||||||||||||||||||||||
19 | 10/2020 | AstraZeneca | Department of Health and Human Services, BARDA | Development, Supply | Phase III | AZD7442 long-acting antibody combination to treat COVID-19 | Link | 486.00 | Yes | PR | Infectious-Viral | Coronavirus | Monoclonals | AZD7442, AZD-8895 + AZD-1061 | Antiviral | 2019-nCoV (SARS-CoV-2) (COVID-19) | 486.00 | ||||||||||||||||||||||||
20 | 10/2020 | Rentschler Biopharma | BioNTech | Supply | Phase III | cGMP manufacturing services for mRNA-based vaccine candidate against SARS-CoV-2 | Link | Yes | PR | Infectious-Viral | Coronavirus | Vaccines | |||||||||||||||||||||||||||||
21 | 10/2020 | Yale | IsoPlexis | Research | Diagnostic | COVID-19 immune profiling biomarkers | Link | Yes | PR | Infectious-Viral | Coronavirus | Diagnostics | |||||||||||||||||||||||||||||
22 | 10/2020 | Cobra Biologics | Scancell | Supply | Preclinical | Production of plasmid to generate DNA vaccine against SARS-CoV-2 | Link | Yes | PR | Infectious-Viral | Coronavirus | Vaccines | |||||||||||||||||||||||||||||
23 | 10/2020 | FibroGenesis | R4D Biotech | License | Preclinical | PneumoBlast cell therapy to treat acute respiratory distress syndrome in COVID-19 patients | Link | Yes | PR | Infectious-Viral, Respiratory | Coronavirus, Other Respiratory | Cell Therapy - Stem Cells/Factors | South America | ||||||||||||||||||||||||||||
24 | 09/2020 | Thermo Fisher Scientific | Humanigen | Supply | Phase III | Expanded manufacturing capacity for COVID-19 therapeutic candidate lenzilumab | Link | Yes | PR | Infectious-Viral | Coronavirus | Monoclonals | |||||||||||||||||||||||||||||
25 | 09/2020 | IriSys | TFF Pharmaceuticals | Supply | Inhalable lung medication with potential to treat COVID-19 and invasive pulmonary aspergillosis | Link | Yes | PR | Infectious-Viral, Respiratory | Coronavirus | Drug Delivery | Other | |||||||||||||||||||||||||||||
26 | 09/2020 | Clene Nanomedicine | Tottenham Acquisition, Chelsea Worldwide | Acquisition | Phase III | Reverse merger agreement, combined public company to be named Clene Inc | Link | Yes | PR | Central Nervous System, Infectious-Viral | Alzheimer's Disease, Coronavirus, Multiple Sclerosis, Parkinson's Disease | ||||||||||||||||||||||||||||||
27 | 09/2020 | Purdue University | PhysIQ | Research | Algorithms to detect early signs of COVID-19 from biometric smartwatch data | Link | Yes | PR | Infectious-Viral | Coronavirus | |||||||||||||||||||||||||||||||
28 | 09/2020 | BioSig Technologies, ViralClear Pharmaceuticals | Sorrento Therapeutics | Research | Evaluation of small molecule and antibody combination therapies against COVID-19 | Link | Yes | PR | Infectious-Viral | Coronavirus | Monoclonals, Synthetics | ||||||||||||||||||||||||||||||
29 | 09/2020 | ABEC | Serum Institute of India | Supply | Manufacture of NVX-CoV2373 COVID-19 vaccine candidate | Link | Yes | PR | Infectious-Viral | Coronavirus | Vaccines | COVID-19 vaccine, NVX-CoV2373 | Vaccine | Protein Subunit | 2019-nCoV (SARS-CoV-2) (COVID-19) | ||||||||||||||||||||||||||
30 | 09/2020 | Bachem | NeuroRx, Relief Therapeutics | Supply | Manufacture of RLF-100 (aviptadil) drug substance for COVID-19 infection with respiratory failure | Link | Yes | PR | Infectious-Viral, Respiratory | Coronavirus, Other Respiratory | Peptides | Invicorp, aviptadil, RLF-100 | Peptide Hormone | vasoactive intestinal peptide receptor agonists | |||||||||||||||||||||||||||
31 | 09/2020 | Lumen Bioscience | US Army Medical Research and Development Command | Research | $4M grant to develop nanobody-based Covid-19 therapeutic | Link | 4.00 | Yes | PR | Infectious-Viral | Coronavirus | Monoclonals | 4.00 | ||||||||||||||||||||||||||||
32 | 09/2020 | Grand River Aseptic Manufacturing | Johnson & Johnson, Janssen | Supply | Technical transfer and fill and finish manufacture of SARS-CoV-2 vaccine candidate | Link | Yes | PR | Infectious-Viral | Coronavirus | Vaccines | ||||||||||||||||||||||||||||||
33 | 09/2020 | Endo International, Par Sterile Products | Novavax | Supply | Fill-finish manufacturing services for NVX-CoV2373 COVID-19 vaccine candidate | Link | Yes | PR | Infectious-Viral | Coronavirus | Vaccines | COVID-19 vaccine, NVX-CoV2373 | Vaccine | Protein Subunit | 2019-nCoV (SARS-CoV-2) (COVID-19) | ||||||||||||||||||||||||||
34 | 09/2020 | Novartis | BioNTech | Asset Purchase | GMP certified manufacturing facility in Germany to expand COVID-19 vaccine production capacity | Link | Yes | PR | Infectious-Viral | Coronavirus | Vaccines | ||||||||||||||||||||||||||||||
35 | 09/2020 | List Biological Laboratories | BetterLife Pharma | Supply | Phase II | Manufacture of AP-003 interferon alpha 2b to treat COVID-19 | Link | Yes | PR | Infectious-Viral | Coronavirus | Recombinant DNA | AP-003 | Antiviral | interferon alpha 2b (IFNa2b) | Inhibitor | |||||||||||||||||||||||||
36 | 09/2020 | Zymeworks | ImmunoPrecise Antibodies | License, Research | Azymetric and EFECT platforms to develop SARS-CoV-2 antibody against COVID-19 | Link | Yes | PR | Infectious-Viral | Coronavirus | Monoclonals | ||||||||||||||||||||||||||||||
37 | 09/2020 | Lonza | Humanigen | Supply | Phase III | Manufacture of Lenzilumab COVID-19 candidate | Link | Yes | PR | Infectious-Viral | Coronavirus | Monoclonals | lenzilumab, KB003 | Antiviral | colony stimulating factor 2 receptor, alpha, low-affinity (granulocyte-macrophage) (CSF2RA) (GMR) (CD116) (GM-CSF-R-alpha) | ||||||||||||||||||||||||||
38 | 09/2020 | IncellDx | MD Biosciences | License | Diagnostic | COVID-19/cytokine storm cytokine panel and CCR5 receptor occupancy in the US and EU | Link | Yes | PR | Infectious-Viral | Coronavirus | Diagnostics | Europe, NAFTA | ||||||||||||||||||||||||||||
39 | 09/2020 | Dynavax Technologies | Valneva | Supply | CpG 1018 adjuvant for use in VLA2001 SARS-CoV-2 vaccine candidate | Link | Yes | PR | Infectious-Viral | Coronavirus | Adjuvant, Vaccines | VLA2001 | Vaccine | Inactivated | 2019-nCoV (SARS-CoV-2) (COVID-19) | ||||||||||||||||||||||||||
40 | 09/2020 | HiFiBiO | ABL Bio | Co-Development, License | Preclinical | HFB30132A SARS-CoV-2 neutralizing antibody for COVID-19 | Link | Yes | PR | Infectious-Viral | Coronavirus | Monoclonals | HFB30132A, HFB-3013 | Antiviral | 2019-nCoV (SARS-CoV-2) (COVID-19) | Inhibitor | |||||||||||||||||||||||||
41 | 09/2020 | Vaxess Technologies | Medigen Vaccine Biologics | Development, License | Formulation | MIMIX patch system to deliver COVID-19 and quadrivalent seasonal influenza vaccine | Link | Yes | PR | Infectious-Viral | Coronavirus, Influenza | Drug Delivery, Vaccines | Transdermal | ||||||||||||||||||||||||||||
42 | 09/2020 | Arctoris | Syntekabio | Letter of Intent, License, Research | Discovery | AI-driven drug discovery to assess small molecule therapeutics for COVID-19 | Link | Yes | PR | Infectious-Viral | Coronavirus | Screening, Synthetics | Small Molecule | ||||||||||||||||||||||||||||
43 | 09/2020 | Aditx Therapeutics | Salveo Diagnostics | License | Diagnostic | AditxtScore Platform for COVID-19 to detect antibodies against SARS-CoV-2 antigens | Link | Yes | PR | Infectious-Viral | Coronavirus | Diagnostics | |||||||||||||||||||||||||||||
44 | 09/2020 | Thermo Fisher Scientific | Inovio Pharmaceuticals | Letter of Intent, Supply | Manufacture of INO-4800 DNA COVID-19 vaccine candidate | Link | Yes | PR | Infectious-Viral | Coronavirus | Vaccines | INO-4800 | Vaccine | DNA | 2019-nCoV (SARS-CoV-2) (COVID-19) | ||||||||||||||||||||||||||
45 | 09/2020 | Relation Therapeutics | Bill & Melinda Gates Foundation | Research | Grant to support machine learning to identify repurposed drug combinations for COVID-19 | Link | 1.30 | Yes | PR | Infectious-Viral | Coronavirus | 1.30 | |||||||||||||||||||||||||||||
46 | 09/2020 | MicroGEM | NIH | Development | Diagnostic | Funding to support development of fast-track rapid, no-lab COVID-19 saliva test | Link | 40.90 | Yes | PR | Infectious-Viral | Coronavirus, Influenza | Diagnostics | 40.90 | |||||||||||||||||||||||||||
47 | 08/2020 | Serum Institute of India | GAVI the Vaccine Alliance, Bill & Melinda Gates Foundation | Supply | 100 million doses of COVID-19 vaccines for low-income countries, expanded to 200 million doses | Link | 300.00 | Yes | PR | Infectious-Viral | Coronavirus | Vaccines | 300.00 | ||||||||||||||||||||||||||||
48 | 08/2020 | Fio | Relay Medical | Joint Venture | Diagnostic, Device | Joint venture to accelerate adaption of Fionet data-and-device platform for COVID-19 testing | Link | Yes | PR | Infectious-Viral | Coronavirus | Diagnostics | |||||||||||||||||||||||||||||
49 | 08/2020 | AllStar Health Brands | TPT Global Tech | Distribution | Diagnostic | QuikLAB Rapid Covid-19 Testing Lab Modules | Link | Yes | PR | Non-exclusive | Infectious-Viral | Coronavirus | Diagnostics | NAFTA, South America | |||||||||||||||||||||||||||
50 | 08/2020 | NOWDiagnostics | Department of Health and Human Services, BARDA | Development | Diagnostic | ADEXUSDx COVID-19 rapid antibody test | Link | Yes | PR | Infectious-Viral | Coronavirus | Diagnostics | |||||||||||||||||||||||||||||
51 | 08/2020 | Humanetics | Pharmaceutics International | Research | Clinical evaluation of BIO 300 in COVID-19 patients | Link | Yes | PR | Infectious-Viral, Respiratory | Coronavirus | BIO 300, genistein nanoparticle | apoptosis, protein tyrosine kinase (PTK) | Inhibitor | ||||||||||||||||||||||||||||
52 | 08/2020 | IriSys | Qualigen | Supply | Preclinical | Manufacture of AS1411 drug product to treat viral diseases including COVID-19 | Link | Yes | PR | Infectious-Viral | Coronavirus | AS1411, ACT-GRO-777, AGRO-100 | DNA/RNA Disruption | apoptosis | Stimulant | ||||||||||||||||||||||||||
53 | 08/2020 | Sugentech | Avellino Labs | Distribution, License | Diagnostic | COVID-19 rapid diagnostic serology test and ELISA to detect COVID-19 antibodies | Link | Yes | PR | Infectious-Viral | Coronavirus | Diagnostics | |||||||||||||||||||||||||||||
54 | 08/2020 | Sinovac Biotech | Bio Farma | License, Supply | Phase III | CoronaVac inactivated vaccine candidate against COVID-19 | Link | Yes | PR | Infectious-Viral | Coronavirus | Vaccines | CoronaVac | Vaccine | Inactivated | 2019-nCoV (SARS-CoV-2) (COVID-19) | |||||||||||||||||||||||||
55 | 08/2020 | Harvard | AbbVie | Research | Emergent viral disease research with focus on coronavirus and viruses that lead to hemorrhagic fever | Link | 30.00 | Yes | PR | Infectious-Viral | Coronavirus | Monoclonals, Synthetics | Small Molecule | 30.00 | 30.00 | ||||||||||||||||||||||||||
56 | 08/2020 | NantKwest | ImmunityBio | Co-Development, License | COVID-19 therapeutics and vaccine candidates | Link | Yes | PR | Infectious-Viral | Coronavirus | Cell Therapy - Stem Cells/Factors, Vaccines | ||||||||||||||||||||||||||||||
57 | 08/2020 | CytoSorbents | Terumo | Distribution, License | Device | CytoSorb extracorporeal cytokine adsorber for use in critically ill COVID-19 patients | Link | Yes | PR | Infectious-Viral | Coronavirus | Device | |||||||||||||||||||||||||||||
58 | 08/2020 | Avid Bioservices | Oragenics | Supply | CDMO services to support development of Terra CoV-2 vaccine candidate for COVID-19 | Link | Yes | PR | Infectious-Viral | Coronavirus | Vaccines | ||||||||||||||||||||||||||||||
59 | 08/2020 | Regeneron Pharmaceuticals | Roche | Co-Development, Distribution | Phase III | Distribution of REGN-COV2 anti-viral antibody cocktail to prevent and treat COVID-19 outside the US | Link | Yes | PR | Infectious-Viral | Coronavirus | Monoclonals | REGN-COV2, REGN-10933+ REGN-10987 | Antiviral | 2019-nCoV (SARS-CoV-2) (COVID-19) | Companies will jointly fund and execute certain ongoing clinical studies. Roche will be responsible for distribution outside the U.S. | |||||||||||||||||||||||||
60 | 08/2020 | Utrecht University, Harbour BioMed, Erasmus | Viroclinics Biosciences, Kiadis Pharma | Development | Monoclonal antibody and natural killer cell combination therapy to treat COVID-19 | Link | Yes | PR | Infectious-Viral | Coronavirus | Cell Therapy - Stem Cells/Factors, Monoclonals | ||||||||||||||||||||||||||||||
61 | 08/2020 | BioSymetrics | Johnson & Johnson, Janssen | Research | Contingent-AI machine learning to predict onset and severity of COVID-19 in different populations | Link | Yes | PR | Infectious-Viral | Coronavirus | |||||||||||||||||||||||||||||||
62 | 08/2020 | Aragen Bioscience | NorthStar Medical Radioisotopes, Monopar Therapeutics | CRO | CRO services to select uPRIT lead candidate to advance into IND-enabling development for COVID-19 | Link | Yes | PR | Infectious-Viral | Coronavirus | |||||||||||||||||||||||||||||||
63 | 08/2020 | Indiana Biosciences Research Institute | BioMEMs Analytics | License | Diagnostic | BioMEMs and SIERRA Reagent to diagnose COVID-19 and other infectious diseases | Link | Yes | PR | Infectious-Viral | Coronavirus | Diagnostics | |||||||||||||||||||||||||||||
64 | 08/2020 | Generex Biotechnology | Bintai Kinden | Letter of Intent, License | Ii-Key-SARS-CoV-2 vaccine for COVID-19 in Malaysia | Link | Yes | PR | Infectious-Viral | Coronavirus | Vaccines | Asia | |||||||||||||||||||||||||||||
65 | 08/2020 | Therapure | VBI Vaccines | Supply | Manufacture of vaccine drug substance for coronavirus vaccine candidates | Link | Yes | PR | Infectious-Viral | Coronavirus | Vaccines | ||||||||||||||||||||||||||||||
66 | 08/2020 | Arcturus Therapeutics | Israeli Ministry of Health | Supply | ARCT-021 STARR mRNA vaccine candidate for COVID-19 | Link | Yes | PR | Infectious-Viral | Coronavirus | Vaccines | Middle East | ARCT-021, LUNAR-COV19, LUNAR-COVID19 | Vaccine | mRNA | 2019-nCoV (SARS-CoV-2) (COVID-19) | |||||||||||||||||||||||||
67 | 08/2020 | George Washington University | Hoth Therapeutics | License, Warrant | Diagnostic, Device | Device to detect the presence of SARS-CoV-2 | Link | Yes | SEC Redacted | Exclusive | Infectious-Viral | Coronavirus | Device, Diagnostics | Worldwide | 72.5K warrants @ $2.76/sh, per Hoth's 6Q20 | mid single-digit royalty, per Hoth's 6Q20 | ||||||||||||||||||||||||||
68 | 08/2020 | CytoSorbents | Surgical Partners | Distribution, License | Device | CytoSorb extracorporeal cytokine adsorber for use in COVID-19 patients with respiratory failure | Link | Yes | PR | Infectious-Viral, Respiratory | Coronavirus | Device | |||||||||||||||||||||||||||||
69 | 08/2020 | CytoSorbents | InvoSurg | Distribution, License | Device | CytoSorb extracorporeal cytokine adsorber for use in COVID-19 patients with respiratory failure | Link | Yes | PR | Infectious-Viral, Respiratory | Coronavirus | Device | |||||||||||||||||||||||||||||
70 | 08/2020 | Coronavirus Immunotherapy Consortium | HiFiBiO | Research | Discovery | Evaluation of neutralizing antibodies against SARS-CoV-2 | Link | Yes | PR | Infectious-Viral | Coronavirus | Monoclonals | |||||||||||||||||||||||||||||
71 | 08/2020 | Centers for Disease Control, Department of Defense, Department of Health and Human Services | McKesson | Distribution | COVID-19 vaccine distribution to support Operation Warp Speed | Link | Yes | PR | Infectious-Viral | Coronavirus | Vaccines | ||||||||||||||||||||||||||||||
72 | 08/2020 | Columbia University | IsoPlexis | Research | Single-Cell Secretome immune profiling solutions to advance COVID-19 vaccine development | Link | Yes | PR | Infectious-Viral | Coronavirus | Vaccines | ||||||||||||||||||||||||||||||
73 | 08/2020 | BioHit Healthcare | ThermoGenesis | Supply | Diagnostic | SARS-CoV-2 IgM/IgG Antibody Test Kit | Link | Yes | Yes | SEC Redacted | Non-exclusive | Infectious-Viral | Coronavirus | Diagnostics | |||||||||||||||||||||||||||
74 | 08/2020 | SK bioscience | Novavax | Supply | Manufacture of antigen component of NVX-CoV2373 COVID-19 vaccine candidate | Link | Yes | PR | Infectious-Viral | Coronavirus | Vaccines | COVID-19 vaccine, NVX-CoV2373 | Vaccine | Protein Subunit | 2019-nCoV (SARS-CoV-2) (COVID-19) | ||||||||||||||||||||||||||
75 | 08/2020 | TFF Pharmaceuticals | UNION therapeutics | License, Option | Formulation | Thin Film Freezing technology to develop dry powder formulations of niclosamide for COVID-19 | Link | 210.00 | Yes | PR | Exclusive | Infectious-Viral | Coronavirus | Drug Delivery | Other | Worldwide | niclosamide, ANA-001, BAY 2353, NSC-178296, WR 46234 | Antiviral | signal transducer and activator of transcription 3 (STAT3) | Inhibitor | 210.00 | Tiered single-digit royalties | $210M in development, regulatory and sales milestones | |||||||||||||||||||
76 | 08/2020 | GenScript Biotech | Beroni Group | Services | CDMO platform to advance study to develop nanobodies to treat COVID-19 | Link | Yes | PR | Infectious-Viral | Coronavirus | |||||||||||||||||||||||||||||||
77 | 08/2020 | Quotient | ANA Therapeutics | Supply | Manufacture of Niclosamide for COVID-19 pivotal clinical trials | Link | Yes | PR | Infectious-Viral | Coronavirus | Synthetics | Small Molecule | niclosamide, ANA-001, BAY 2353, NSC-178296, WR 46234 | Antiviral | signal transducer and activator of transcription 3 (STAT3) | Inhibitor | |||||||||||||||||||||||||
78 | 08/2020 | IsoTherapeutics | NorthStar Medical Radioisotopes, Monopar Therapeutics | Supply | Manufacture of radio-immuno-therapeutic to treat severe COVID-19 | Link | Yes | PR | Infectious-Viral | Coronavirus | Monoclonals | Conjugates | |||||||||||||||||||||||||||||
79 | 08/2020 | Pfizer | Gilead | Supply | Approved | Manufacture of remdesivir to treat COVID-19 | Link | Yes | PR | Infectious-Viral | Coronavirus | Synthetics | Small Molecule | Veklury, remdesivir, GS-5734 | Antiviral | replicase polyprotein 1ab, RNA-directed RNA polymerase L | Inhibitor | ||||||||||||||||||||||||
80 | 08/2020 | ADial Pharmaceuticals | Brik | Distribution | Diagnostic | Rapid Result COVID-19 antibody test kit | Link | Yes | PR | Infectious-Viral | Coronavirus | Diagnostics | |||||||||||||||||||||||||||||
81 | 08/2020 | Novavax | Serum Institute of India | Distribution, License, Supply | NVX-CoV2373 COVID-19 vaccine candidate in low- and middle-income countries and India | Link | Yes | PR | Exclusive | Infectious-Viral | Coronavirus | Adjuvant, Vaccines | Asia | COVID-19 vaccine, NVX-CoV2373 | Vaccine | Protein Subunit | 2019-nCoV (SARS-CoV-2) (COVID-19) | ||||||||||||||||||||||||
82 | 08/2020 | Aegea Biotechnologies | Biocept | Co-Development, License, Option | Diagnostic | PCR-based COVID-19 assay utilizing Switch-Blocker technology | Link | Yes | PR | Infectious-Viral | Coronavirus | Diagnostics | |||||||||||||||||||||||||||||
83 | 08/2020 | Shenzhen Kangtai Biological Products | AstraZeneca | Supply | Manufacture of AZD1222 COVID-19 vaccine | Link | Yes | PR | Infectious-Viral | Coronavirus | Vaccines | COVID-19 vaccine, ChAdOx1, AZD1222 | Vaccine | Nonreplicating Viral Vector | 2019-nCoV (SARS-CoV-2) (COVID-19) | ||||||||||||||||||||||||||
84 | 08/2020 | Johnson & Johnson, Janssen | Department of Health and Human Services, Department of Defense, BARDA | Supply | 100 million doses of Ad26.COV2.S vaccine against COVID-19 | Link | Yes | PR | Infectious-Viral | Coronavirus | Vaccines | Ad26.COV2-S, Ad26.COV2.S | Vaccine | Recombinant | 2019-nCoV (SARS-CoV-2) (COVID-19) | ||||||||||||||||||||||||||
85 | 08/2020 | BioNTech, Pfizer | Public Health Agency of Canada | Supply | Phase II | BNT162 mRNA-based vaccine candidate against COVID-19 | Link | Yes | PR | Infectious-Viral | Coronavirus | Vaccines | NAFTA | BNT162 | Vaccine | mRNA | 2019-nCoV (SARS-CoV-2) (COVID-19) | ||||||||||||||||||||||||
86 | 08/2020 | Todos Medical | Pathnova Laboratories | Distribution, License | Diagnostic | COVID-19 and breast cancer tests in Singapore and Southeast Asia | Link | Yes | PR | Cancer, Infectious-Viral | Breast, Coronavirus | Diagnostics | Asia | ||||||||||||||||||||||||||||
87 | 07/2020 | Regeneron Pharmaceuticals | Department of Health and Human Services, Department of Defense, BARDA | Supply | Phase II | Manufacture of REGN-COV2 antibody cocktail to treat COVID-19 under Warp Speed Program | Link | 450.00 | Yes | PR | Infectious-Viral | Coronavirus | Monoclonals | REGN-COV2, REGN-10933+ REGN-10987 | Antiviral | 2019-nCoV (SARS-CoV-2) (COVID-19) | 450.00 | ||||||||||||||||||||||||
88 | 07/2020 | Valneva | UK Government | Supply | 60 million doses of VLA2001 SARS-CoV-2 vaccine candidate for COVID-19 | Link | Yes | PR | Infectious-Viral | Coronavirus | Adjuvant, Vaccines | VLA2001 | Vaccine | Inactivated | 2019-nCoV (SARS-CoV-2) (COVID-19) | ||||||||||||||||||||||||||
89 | 07/2020 | Humanetics | NIH, National Institute of Allergy and Infectious Diseases | Research | Funding to support testing of BIO 300 in COVID-19 patients | Link | Yes | PR | Infectious-Viral, Respiratory | Coronavirus | BIO 300, genistein nanoparticle | apoptosis, protein tyrosine kinase (PTK) | Inhibitor | ||||||||||||||||||||||||||||
90 | 07/2020 | SmartPharm | Sorrento Therapeutics | Acquisition, Letter of Intent | Acquisition for undisclosed terms | Link | Yes | PR | Cancer, Infectious-Viral | Broad Focus Cancer, Coronavirus | |||||||||||||||||||||||||||||||
91 | 07/2020 | NIH | Humanigen | CRO | Phase II | Lenzilumab in a COVID clinical trial | Link | Yes | Yes | SEC Full | Infectious-Viral | Coronavirus | Monoclonals | lenzilumab, KB003 | Antiviral | colony stimulating factor 2 receptor, alpha, low-affinity (granulocyte-macrophage) (CSF2RA) (GMR) (CD116) (GM-CSF-R-alpha) | |||||||||||||||||||||||||
92 | 07/2020 | CytoDyn | American Reagent | Distribution | Phase II | PRO140 (leronlimab) for the treatment of COVID-19 in US | Link | Yes | SEC Redacted | Exclusive | Infectious-Viral | Coronavirus | Monoclonals | Humanized Abs | NAFTA | leronlimab, PRO 140, PA-14, WHO 10751, PRO140 | Antiviral | anti-CCR5 humanized IgG4 monoclonal antibody inhibitor | CC chemokine receptor type 5 (CCR5) (CD195) | Antagonist | |||||||||||||||||||||
93 | 07/2020 | Emery Pharma | Halodine | CRO | CRO services to support development of oral and nasal antiseptics active against COVID-19 | Link | Yes | PR | Infectious-Viral | Coronavirus | |||||||||||||||||||||||||||||||
94 | 07/2020 | Becton Dickinson | Department of Defense, Department of Health and Human Services | Supply | Diagnostic | Funding to scale up US manufacturing of BD Veritor Solution for Rapid Detection of SARS-CoV-2 | Link | 24.00 | Yes | PR | Infectious-Viral | Coronavirus | Diagnostics | 24.00 | |||||||||||||||||||||||||||
95 | 07/2020 | Precipio | ADS Biotec | Distribution | Diagnostic | COVID-19 serology antibody tests | Link | Yes | PR | Infectious-Viral | Coronavirus | Diagnostics | |||||||||||||||||||||||||||||
96 | 07/2020 | Medigen Biotech | Alercell | Distribution | Diagnostic | COVID-19 rapid antibody serology tests | Link | 280.00 | Yes | PR | Infectious-Viral | Coronavirus | Diagnostics | 280.00 | |||||||||||||||||||||||||||
97 | 07/2020 | BioNTech, Pfizer | Ministry of Health, Labour and Welfare (Japan) | Supply | 120 million doses of BNT162 mRNA-based vaccine candidate against COVID-19 | Link | Yes | PR | Infectious-Viral | Coronavirus | Vaccines | Asia | BNT162 | Vaccine | mRNA | 2019-nCoV (SARS-CoV-2) (COVID-19) | |||||||||||||||||||||||||
98 | 07/2020 | Intravacc | Celonic AG | Research | Preclinical | COVID-19 vaccine combining immunogenic Spike (S) protein of SARS-CoV-2 and OMV technology | Link | Yes | PR | Infectious-Viral | Coronavirus | Vaccines | |||||||||||||||||||||||||||||
99 | 07/2020 | Mesa Biotech | NIH | Development | Diagnostic | Funding to support development of Accula SARS-CoV-2 Test (RADx Program) | Link | 15.40 | Yes | PR | Infectious-Viral | Coronavirus | Diagnostics | 15.40 | |||||||||||||||||||||||||||
100 | 07/2020 | Helix | NIH | Development | Diagnostic | Funding to support rapid scaling of end-to-end COVID-19 test system (RADx Program) | Link | 33.40 | Yes | PR | Infectious-Viral | Coronavirus | Diagnostics | 33.40 |